Association between lipid accumulation product and psoriasis among adults: a nationally representative cross-sectional study.
Lipid accumulation product
NHANES
Obesity
Psoriasis
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
received:
07
03
2024
accepted:
25
04
2024
medline:
18
5
2024
pubmed:
18
5
2024
entrez:
17
5
2024
Statut:
epublish
Résumé
Lipid accumulation product (LAP) is an accessible and relatively comprehensive assessment of obesity that represents both anatomical and physiological lipid accumulation. Obesity and psoriasis are potentially related, according to previous research. Investigating the relationship between adult psoriasis and the LAP index was the goal of this study. This is a cross-sectional study based on data from the National Health and Nutrition Examination Survey (NHANES) 2003-2006 and 2009-2014. The association between LAP and psoriasis was examined using multivariate logistic regression and smoothed curve fitting. To verify whether this relationship was stable across populations, subgroup analyses and interaction tests were performed. The LAP index showed a positive correlation with psoriasis in 9,781 adult participants who were 20 years of age or older. A 27% elevated probability of psoriasis was linked to every unit increase in ln LAP in the fully adjusted model (Model 3: OR 1.27, 95% CI 1.06-1.52). In comparison with participants in the lowest ln LAP quartile, those in the highest quartile had an 83% greater likelihood of psoriasis (Model 3: OR 1.83, 95% CI 1.08-3.11). This positive correlation was more pronounced for young males, participants who had never smoked, non-drinkers, participants who exercised little, as well as non-hypertensive and non-diabetic participants. This study found that the LAP index and adult psoriasis were positively correlated, especially in young males without comorbidities. Therefore, it is proposed that LAP may serve as a biomarker for early diagnosis of psoriasis and tracking the effectiveness of treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Lipid accumulation product (LAP) is an accessible and relatively comprehensive assessment of obesity that represents both anatomical and physiological lipid accumulation. Obesity and psoriasis are potentially related, according to previous research. Investigating the relationship between adult psoriasis and the LAP index was the goal of this study.
METHODS
METHODS
This is a cross-sectional study based on data from the National Health and Nutrition Examination Survey (NHANES) 2003-2006 and 2009-2014. The association between LAP and psoriasis was examined using multivariate logistic regression and smoothed curve fitting. To verify whether this relationship was stable across populations, subgroup analyses and interaction tests were performed.
RESULTS
RESULTS
The LAP index showed a positive correlation with psoriasis in 9,781 adult participants who were 20 years of age or older. A 27% elevated probability of psoriasis was linked to every unit increase in ln LAP in the fully adjusted model (Model 3: OR 1.27, 95% CI 1.06-1.52). In comparison with participants in the lowest ln LAP quartile, those in the highest quartile had an 83% greater likelihood of psoriasis (Model 3: OR 1.83, 95% CI 1.08-3.11). This positive correlation was more pronounced for young males, participants who had never smoked, non-drinkers, participants who exercised little, as well as non-hypertensive and non-diabetic participants.
CONCLUSIONS
CONCLUSIONS
This study found that the LAP index and adult psoriasis were positively correlated, especially in young males without comorbidities. Therefore, it is proposed that LAP may serve as a biomarker for early diagnosis of psoriasis and tracking the effectiveness of treatment.
Identifiants
pubmed: 38760661
doi: 10.1186/s12944-024-02123-y
pii: 10.1186/s12944-024-02123-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
143Informations de copyright
© 2024. The Author(s).
Références
Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940–6.
pubmed: 34190957
doi: 10.1001/jamadermatol.2021.2007
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–60.
pubmed: 32427307
doi: 10.1001/jama.2020.4006
Dauden E, Blasco AJ, Bonanad C, Botella R, Carrascosa JM, González-Parra E, Jodar E, Joven B, Lázaro P, Olveira A, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2018;32:2058–73.
pubmed: 29992631
doi: 10.1111/jdv.15177
Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022;158:745–53.
pubmed: 35612851
pmcid: 9134040
doi: 10.1001/jamadermatol.2022.1609
Vanderpuye-Orgle J, Zhao Y, Lu J, Shrestha A, Sexton A, Seabury S, Lebwohl M. Evaluating the economic burden of psoriasis in the United States. J Am Acad Dermatol. 2015;72:961–e967965.
pubmed: 25882886
doi: 10.1016/j.jaad.2015.02.1099
Wu JJ, Suryavanshi M, Davidson D, Patel V, Jain A, Seigel L. Economic Burden of Comorbidities in patients with psoriasis in the USA. Dermatol Ther (Heidelb). 2023;13:207–19.
pubmed: 36402940
doi: 10.1007/s13555-022-00832-9
Gaskin CJ, Cooper K, Stephens LD, Peeters A, Salmon J, Porter J. Clinical practice guidelines for the management of overweight and obesity published internationally: a scoping review. Obes Rev 2024:e13700.
Rhee EJ. The Influence of Obesity and Metabolic Health on Vascular Health. Endocrinol Metab (Seoul). 2022;37:1–8.
pubmed: 35255597
doi: 10.3803/EnM.2022.101
Donini LM, Pinto A, Giusti AM, Lenzi A, Poggiogalle E. Obesity or BMI Paradox? Beneath the tip of the Iceberg. Front Nutr. 2020;7:53.
pubmed: 32457915
pmcid: 7221058
doi: 10.3389/fnut.2020.00053
Bosello O, Donataccio MP, Cuzzolaro M. Obesity or obesities? Controversies on the association between body mass index and premature mortality. Eat Weight Disord. 2016;21:165–74.
pubmed: 27043948
doi: 10.1007/s40519-016-0278-4
Vecchié A, Dallegri F, Carbone F, Bonaventura A, Liberale L, Portincasa P, Frühbeck G, Montecucco F. Obesity phenotypes and their paradoxical association with cardiovascular diseases. Eur J Intern Med. 2018;48:6–17.
pubmed: 29100895
doi: 10.1016/j.ejim.2017.10.020
Wang S, Shi S, Huang Y, Huang H, Zhong VW. Severity of abdominal obesity and cardiometabolic diseases in US adults. Public Health. 2024;227:154–62.
pubmed: 38232563
doi: 10.1016/j.puhe.2023.12.010
Kahn HS. The lipid accumulation product performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26.
pubmed: 16150143
pmcid: 1236917
doi: 10.1186/1471-2261-5-26
Ebrahimi M, Seyedi SA, Nabipoorashrafi SA, Rabizadeh S, Sarzaeim M, Yadegar A, Mohammadi F, Bahri RA, Pakravan P, Shafiekhani P, et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis. Lipids Health Dis. 2023;22:41.
pubmed: 36922815
pmcid: 10015691
doi: 10.1186/s12944-023-01802-6
Xia C, Li R, Zhang S, Gong L, Ren W, Wang Z, Li Q. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr. 2012;66:1035–8.
pubmed: 22781025
doi: 10.1038/ejcn.2012.83
Nascimento-Ferreira MV, Rendo-Urteaga T, Vilanova-Campelo RC, Carvalho HB, da Paz Oliveira G, Paes Landim MB, Torres-Leal FL. The lipid accumulation product is a powerful tool to predict metabolic syndrome in undiagnosed Brazilian adults. Clin Nutr. 2017;36:1693–700.
pubmed: 28081980
doi: 10.1016/j.clnu.2016.12.020
Ganguly S, Ray L, Kuruvila S, Nanda SK, Ravichandran K. Lipid accumulation product index as visceral obesity indicator in psoriasis: a case-control study. Indian J Dermatol. 2018;63:136–40.
pubmed: 29692455
pmcid: 5903043
Ataseven A, Kutlu R, Uzun L. The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients. North Clin Istanb. 2021;8:203–11.
pubmed: 34222799
pmcid: 8240228
Chen TC, Parker JD, Clark J, Shin HC, Rammon JR, Burt VL. National Health and Nutrition Examination Survey: estimation procedures, 2011–2014. Vital Health Stat 2 2018:1–26.
Phan C, Ezzedine K, Lai C, Le Cleach L, Cogrel O, Fardet L, Wolkenstein P, Chosidow O, Beylot-Barry M, Sbidian E. Agreement between Self-reported inflammatory skin disorders and dermatologists’ diagnosis: a cross-sectional diagnostic study. Acta Derm Venereol. 2017;97:1243–4.
pubmed: 28681066
doi: 10.2340/00015555-2749
Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American heart Association task force on clinical practice guidelines. Circulation. 2018; 138:e426-e483.
Shin JI, Wang D, Fernandes G, Daya N, Grams ME, Golden SH, Rajpathak S, Selvin E. Trends in receipt of American Diabetes Association Guideline-recommended care among U.S. adults with diabetes: NHANES 2005–2018. Diabetes Care. 2021;44:1300–8.
pubmed: 33863753
pmcid: 8247496
doi: 10.2337/dc20-2541
Wu S, Han J, Qureshi AA. Use of aspirin, non-steroidal anti-inflammatory drugs, and acetaminophen (Paracetamol), and risk of psoriasis and psoriatic arthritis: a cohort study. Acta Derm Venereol. 2015;95:217–23.
pubmed: 24691893
doi: 10.2340/00015555-1855
Grželj J, Sollner Dolenc M. The role of xenobiotics in triggering psoriasis. Arch Toxicol. 2020;94:3959–82.
pubmed: 32833044
doi: 10.1007/s00204-020-02870-8
Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:1163–78.
pubmed: 29680995
pmcid: 6290660
doi: 10.1007/s10654-018-0366-z
Han JH, Lee JH, Han KD, Kim HN, Bang CH, Park YM, Lee JY, Kim TY. Increased risk of psoriasis in subjects with abdominal obesity: a nationwide population-based study. J Dermatol. 2019;46:695–701.
pubmed: 31149744
doi: 10.1111/1346-8138.14939
Koebnick C, Black MH, Smith N, Der-Sarkissian JK, Porter AH, Jacobsen SJ, Wu JJ. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159:577–83.
pubmed: 21524758
pmcid: 3168116
doi: 10.1016/j.jpeds.2011.03.006
Nada H, Elakhrass A, Ahmad N, Refaat M. Psoriasis: is it a risk factor for cardiovascular diseases? J Dermatolog Treat. 2022;33:3154–9.
pubmed: 35943349
doi: 10.1080/09546634.2022.2112137
Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2010;76:662–5.
pubmed: 21079309
doi: 10.4103/0378-6323.72462
Wong Y, Nakamizo S, Tan KJ, Kabashima K. An update on the role of adipose tissues in Psoriasis. Front Immunol. 2019;10:1507.
pubmed: 31316526
pmcid: 6609873
doi: 10.3389/fimmu.2019.01507
Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60:329–39.
pubmed: 11681807
doi: 10.1079/PNS200194
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.
pubmed: 14679176
pmcid: 296995
doi: 10.1172/JCI200319246
Kruglikov IL, Scherer PE, Wollina U. Are dermal adipocytes involved in psoriasis? Exp Dermatol. 2016;25:812–3.
pubmed: 26913468
doi: 10.1111/exd.12996
Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449:564–9.
pubmed: 17873860
doi: 10.1038/nature06116
Han SJ, Glatman Zaretsky A, Andrade-Oliveira V, Collins N, Dzutsev A, Shaik J, Morais da Fonseca D, Harrison OJ, Tamoutounour S, Byrd AL, et al. White Adipose tissue is a Reservoir for Memory T Cells and promotes protective memory responses to infection. Immunity. 2017;47:1154–e11681156.
pubmed: 29221731
pmcid: 5773068
doi: 10.1016/j.immuni.2017.11.009
Wolk K, Sabat R. Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord. 2016;17:305–17.
pubmed: 27554109
doi: 10.1007/s11154-016-9381-0
Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–9. quiz 920.
pubmed: 15867843
doi: 10.1016/j.jaci.2005.02.023
Kyriakou A, Patsatsi A, Sotiriadis D, Goulis DG. Serum leptin, Resistin, and adiponectin concentrations in psoriasis: a Meta-analysis of Observational studies. Dermatology. 2017;233:378–89.
pubmed: 29232663
doi: 10.1159/000481882
Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A, Monfrecola G, Balato N, Ayala F, Romanelli M, Balato A. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;12:1299–308.
pubmed: 27322922
doi: 10.1080/1744666X.2016.1201423
Takahashi H, Tsuji H, Honma M, Ishida-Yamamoto A, Iizuka H. Increased plasma resistin and decreased omentin levels in Japanese patients with psoriasis. Arch Dermatol Res. 2013;305:113–6.
pubmed: 23291856
doi: 10.1007/s00403-012-1310-9
Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092–101.
pubmed: 16039994
doi: 10.1016/j.bbrc.2005.06.202
Lynch M, Ahern T, Sweeney CM, Malara A, Tobin AM, O’Shea D, Kirby B. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56:1103–18.
pubmed: 28762474
doi: 10.1111/ijd.13699
Shibata S, Saeki H, Tada Y, Karakawa M, Komine M, Tamaki K. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55:62–3.
pubmed: 19395243
doi: 10.1016/j.jdermsci.2009.02.009
Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007, 157:649–655.
Takahashi H, Tsuji H, Takahashi I, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159:1207–8.
pubmed: 18795929
Shibata S, Tada Y, Hau CS, Mitsui A, Kamata M, Asano Y, Sugaya M, Kadono T, Masamoto Y, Kurokawa M, et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat Commun. 2015;6:7687.
pubmed: 26173479
doi: 10.1038/ncomms8687
Hagino T, Saeki H, Fujimoto E, Kanda N. Effects of Biologic Therapy on Laboratory Indicators of Cardiometabolic Diseases in Patients with Psoriasis. J Clin Med 2023, 12:1934.
Piros ÉA, Szabó Á, Rencz F, Brodszky V, Wikonkál N, Miheller P, Horváth M, Holló P. Anti-interleukin-17 therapy of severe psoriatic patients results in an improvement of serum lipid and inflammatory parameters’ levels, but has no effect on body composition parameters. Life (Basel). 2021;11:535.
pubmed: 34207504